Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 2,185 trials in your specialties ()
View trials across your selected specialties

EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Alcohol Use Disorder
View Full Trial
INTERVENTION

Behavioral: Bias retraining, Behavioral: Sham retraining

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Michigan Addiction Research Center, Ann Arbor, Michigan, United States

Brief Summary

This study investigates the effect of a computerized approach/avoidance retraining (aka cognitive bias modification) over and above treatment as usual for patients in treatment for substance use disorders. The computerized training entails viewing pictures of drug and non-drug related stimuli, and then using the computer to make the drug pictures smaller and the non-drug pictures larger. Participants will also take part in an EEG/event-related brain potential assessment at the beginning and end of treatment to identify brain measures that are associated with treatment response.

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood ...
View Full Trial
INTERVENTION

Other: Laboratory Biomarker Analysis, Drug: Selumetinib, Drug: Selumetinib Sulfate

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States

Brief Summary

This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma...
View Full Trial
INTERVENTION

Biological: Dendritic Cell Vaccine, Biological: Tumor Lysate, Drug: Imiquimod, Procedure: Leukapheresis

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Miami, Miami, Florida, United States

Brief Summary

The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann...
View Full Trial
INTERVENTION

Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Leucovorin Calcium, Drug: Mercaptopurine, Drug: Methotrexate, Drug: Pegaspargase, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Drug: Thioguanine, Drug: Vincristine Sulfate

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States

Brief Summary

This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Primary Immunodeficiency Diseases (PID)
View Full Trial
INTERVENTION

Biological: HYQVIA, Biological: GAMMAGARD LIQUID

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama Medical Center, Birmingham, Alabama, United States

Brief Summary

The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to <16 years) participants with primary immunodeficiency disease (PIDD).

Study Evaluating Subjects With Distal Renal Tubular Acidosis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Distal Renal Tubular Acidosis
View Full Trial
INTERVENTION

Drug: ADV7103, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, San Francisco, California, United States

Brief Summary

This is a phase 3, prospective, multicenter, randomized, double-blinded, placebo-controlled, study product withdrawal study comparing the efficacy of ADV7103 versus placebo in preventing the development of metabolic acidosis defined by serum bicarbonate level in pediatric (6 months to < 18 years of age) and adult (18 to 65 years of age) subjects with primary dRTA.

Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Chronic Hepatitis B Infection
View Full Trial
INTERVENTION

Drug: Tenofovir DF, Drug: TDF Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Phoenix Children's Hospital, Phoenix, Arizona, United States

Brief Summary

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

TITRE III: Influenza B Immunogenicity Investigation

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Influenza
View Full Trial
INTERVENTION

Biological: 2018-19 quadrivalent inactivated influenza vaccine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

British Columbia Centre for Disease Control, Vancouver, British Columbia (BC), Canada

Brief Summary

Each winter, viruses belonging to two kinds of influenza A ("A/H1N1" & "A/H3N2") and two kinds of influenza B ("B/Yamagata" & "B/Victoria") can cause illness. Historically, the yearly influenza vaccine that was recommended in children was designed to protect against both kinds of influenza A but only one kind of influenza B. In a series of trials conducted between 2008-09 and 2010-11 (TITRE I, II, and IIB), the TITRE investigators measured antibody response to influenza B in children who were primed with two doses of trivalent inactivated influenza vaccine (TIV) containing B/Yamagata. Overall, the investigators found that 2 doses of vaccine containing B/Yamagata did not adequately prime children for response to the alternate B/Victoria antigen and that subsequent vaccine doses containing B/Victoria-lineage antigen strongly boosted antibodies to the B/Yamagata antigen that was introduced during first immunization priming, but with lower responses to B/Victoria. For the first time since 2009-10, the recommended B/Victoria component of the seasonal influenza vaccine has been changed, from B/Brisbane/60/2008 to B/Colorado/60/2007 for the coming 2018-19 season. The investigators thus have a unique opportunity to clarify lineage-specific influenza B responses in a well-characterized cohort of children originally primed to Yamagata. The investigators' main interest is to assess whether TITRE I children primed with two doses of B/Yamagata in 2008-09 have since or are now capable of achieving a sufficient antibody response to B/Victoria following a single dose of 2018-19 QIV, ten years after their initial TIV B/Yamagata priming exposure.

Dendritic Cell Vaccine for Children and Adults With Sarcoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma
View Full Trial
INTERVENTION

Biological: Dendritic Cells Vaccine, Biological: Lysate of Tumor, Drug: Gemcitabine, Drug: Imiquimod, Procedure: Leukapheresis

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Miami, Miami, Florida, United States

Brief Summary

The use of adjuvant vaccination with autologous dendritic cells (DC) matured in situ after being loaded with tumor lysates derived from autologous refractory sarcoma tissue will be safe, feasible and potentially beneficial for patients diagnosed with sarcoma. This vaccination will result in evidence of immune stimulation against tumor antigens. In addition, combining myeloid derived supressor cells (MDSC) inhibition using gemcitabine with DC vaccination in this method will be safe and feasible and show improved immune parameters over DC vaccination without MDSC inhibition.

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Bronchopulmonary Dysplasia
View Full Trial
INTERVENTION

Biological: UNEX-42, Biological: Phosphate-buffered saline

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Colorado Hospital, Aurora, Colorado, United States

Brief Summary

A multicenter, placebo-controlled, randomized, dose escalation, safety, and tolerability study of UNEX-42 in infants born at <27 weeks of GA at high risk for BPD.